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1. Introduction 
Parkinsonian syndromes are a heterogeneous entity of movement disorders, which can be 
subdivided into idiopathic Parkinson’s disease, rare genetic forms of Parkinson’s disease as 
well as symptomatic and atypical parkinsonian syndromes. In addition, a number of other 
neurodegenerative disorders may show clinical signs of Parkinsonism. The etiology, 
histopathology, clinical manifestation and disease course varies significantly among these 
disorders. A correct and early differential diagnosis therefore is essential for proper 
prognostic estimation and consultancy of the patient as well as a prerequisite for inclusion 
in clinical studies.  
This chapter will summarize diagnostic criteria mainly focussing on the diagnosis of 
idiopathic Parkinson’s disease (iPD) and delineate specific factors to differentiate this 
disorder from other disease entities.  
2. Clinical signs 
Idiopathic Parkinson’s disease is a progressive, neurodegenerative movement disorder, 
which in its most classical manifestation is characterized by the triad of bradykinesia, 
muscular rigidity and tremor. IPD is the most frequent neurodegenerative movement 
disorder with a mean prevalence of ~150/100.000 (Errea et al., 1999; Walker et al., 2010). A 
definite diagnosis has to be based on histopathological analysis and requires cell loss in the 
substantia nigra, the presence of Lewy bodies, which stain for alpha-synuclein and 
ubiquitin, and usually can be obtained only post mortem. In addition, the histology has to 
exclude histopathological features of other disorders, which could mimick clinical PD, such 
as atypical parkinsonian syndromes (Gelb et al., 1999). While these criteria are useful for 
post mortem classification, several attempts have been made to define clinical diagnostic 
criteria, e.g. by the UK Parkinson’s Disease Society Brain Bank (UKPDSBB) (Hughes et al., 
1992) or the National Institute of Neurological Disorders and Stroke (NINDS) (Gelb et al., 
1999). For clinical practice, the implementation of modified UKPDSBB criteria has proven 
useful: here, the diagnosis is based on (1) the identification of parkinsonian symptoms, (2) 
the absence of exclusion criteria and (3) the presence of prospective positive criteria  
(Table 1). However, it has to be kept in mind, that even if these criteria are verified by expert 
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neurologists, the diagnostic certainty is only between 75 - 90 % when compared with the 
results of the autopsy (Hughes et al., 2001; Dickson et al., 2009). 
 
Step 1 Diagnosis of Parkinsonian syndrome 
- Bradykinesia (slowness of initiation of voluntary movement with  
  progressive reduction in speed and amplitude of repetitive actions) 
- and at least one of the following: 
 - muscular rigidity 
 - 4-6 Hz rest tremor 
 - postural instability not caused by primary visual, vestibular,  
   cerebellar, or proprioceptive dysfunction 
 
Step 2 Exclusion criteria for idiopathic Parkinson’s disease 
- Repeated strokes with stepwise progression of parkinsonian features 
- Repeated head injury 
- History of definite encephalitis 
- Oculogyric crises 
- Neuroleptic treatment at onset of symptoms 
- More than one affected relative 
- Sustained remission 
- Strictly unilateral features after 3 years 
- Supranuclear gaze palsy 
- Cerebellar signs 
- Early severe autonomic involvement 
- Early severe dementia with disturbances of memory, language, and praxis 
- Babinski sign 
- Presence of cerebral tumour or communicating hydrocephalus on CT scan 
- Negative response to large doses of levodopa (if malabsorption excluded) 
- MPTP exposure 
 
Step 3 Supportive prospective positive criteria for idiopathic Parkinson’s disease (Three 
or more required for diagnosis of definite Parkinson's disease) 
- Unilateral onset 
- Rest tremor present 
- Progressive disorder 
- Persistent asymmetry affecting side of onset most 
- Excellent response (70-100%) to levodopa 
- Severe levodopa-induced chorea 
- Levodopa response for 5 years or more 
- Clinical course of 10 years or more 
Table 1. UK Parkinson’s Disease Society Brain Bank (UKPDSBB) clinical diagnostic criteria 
for idiopathic Parkinson’s disease (from (Hughes et al., 1992). 
Although numerous supplementary technical exams are available, which may increase 
diagnostic certainty, the initial diagnosis remains a clinical one and can be based purely on 
medical history and clinical examination. Motor symptoms in iPD are clinically most 
striking, but a number of less prominent non-motor symptoms may already be present at 
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onset. These non-motor symptoms (such as olfactory dysfunction or altered sleep 
behaviour) have not yet been sufficiently recognized in structured diagnostic criteria, but 
are likely to be included in the future. The importance of non-motor symptoms is further 
underlined by recent studies suggesting a premotor phase ranging from 5 – 20 years before 
the onset of motor symptoms (Savica et al., 2010). Even more importantly, when patients 
were asked about the impact of symptoms on health-related quality of life autonomic 
dysfunction, psychiatric complications, pain, fatigue, and sleep problems were mainly 
correlated with a negative impact (Gallagher et al., 2010). 
IPD has been observed in all age groups, but about 75 % of all cases show first motor 
symptoms after an age of 60. Age is the single most consistent risk factor for developing iPD 
and should be considered in the differential diagnosis (Hindle, 2010). Only ~ 5 % of all PD 
cases begin before the age of 40 and these are likely to be caused by genetic mutations 
(Wickremaratchi et al., 2009).  
2.1 Motor symptoms 
The initial presentation may vary, with tremor beeing the most common motor symptom in 
patients, in which the diagnosis of iPD has been verified post-mortem (Hughes et al., 1993). A 
recent community-based study in 358 patients identified tremor as initially leading symptom 
in approximately half of the patients. Some 44 % showed an akinetic-rigid phenotype and only 
7 % presented with a leading gait disturbance. Interestingly, the akinetic-rigid presentation 
was more pronounced in younger patients, while tremor and gait disturbance as initial 
symptoms increase with the age at presentation (Wickremaratchi et al., 2011). 
2.1.1 Bradykinesia 
Slowness of initiation and execution of voluntary movements, such as limb movements, 
facial expression or gait, characterizes bradykinesia. Diadochokinesis (the ability to perform 
rapid alternating movements) is usually slowed (Haaxma et al., 2010). Micrographia with a 
characteristic decrease of character size towards the end of the line, the shuffling gait with a 
diminished gait quadrangle and reduced arm swing, and hypomimia with a progressive 
loss of facial expression are classical manifestations of bradykinesia. Because of the severe 
hypomimia with a lack to adequately support emotional expression, PD patients may 
wrongly be considered depressive. At the same time, one has to keep in mind that 
depression is a common concomitant disorder, which may occur in up to ~ 20 % of PD 
patients (Brown et al., 2011).  
2.1.2 Tremor 
The characteristic tremor is a low-frequency (4-6 Hz) resting tremor, but other tremor forms, 
such as an action tremor or a postural tremor may occur as the disease progresses (Jankovic 
et al., 1999). Other tremor entities, most importantly essential tremor (ET), have to be 
considered in the differential diagnosis and tremor frequency is a major differentiation 
criterion (see part 4.4). Therefore, a tremor analysis may be a helpful additional examination 
to quantify the characteristics of the tremor presented. There is evidence to suggest that 
there is an association and even histopathological overlap in some cases of ET and iPD, but 
the case is not yet closed on this issue (Raethjen and Deuschl, 2009). Like most symptoms in 
iPD, the tremor manifests with a unilateral preference. In the course of the disease, tremor 
intensity may diminish and give way to the bradykinetic symptoms. Very importantly one 
has to note, that about one of four of all iPD patients does not develop a characteristic 
tremor during the entire course of the disease (Hughes et al., 1993).  
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2.1.3 Rigidity 
Rigidity becomes apparent at the clinical examination, when the passive movement of a 
limb is impaired by a wax-like resistance. In combination with the tremor frequency this 
results in the cogwheel phenomenon upon passive movement in a joint. Many patients with 
iPD initially complain of unilateral back and/or shoulder pain as a consequence of the 
asymetric muscular tone, which may result in the consultation of an orthopedic specialist 
before final referral to a neurologist (Madden and Hall, 2010).  
2.1.4 Postural instability 
Postural instability regularly appears in the course of the disease, most often in more 
advanced stages (Coelho et al., 2010). In progressive disease it may be considered as 
important diagnostic feature and supports the initial diagnosis (Hughes et al., 1992). 
However, pronounced postural instability at the initial presentation may be an indicator for 
progressive supranuclear palsy (PSP) instead of iPD (Litvan et al., 1996) and therefore has to 
be carefully set into context with other motor features.  
Usually the motor symptoms are asymetrically distributed and in cases with a strict bilateral 
presentation one should consider the differential diagnosis of a symptomatic or atypical 
parkinsonian syndrome.  
2.2 Non-motor symptoms 
Since the landmark studies of Braak and colleagues the picture of iPD as a mainly 
nigrostriatal disorder is no longer sustainable. In fact, these analyses suggest that the 
pathoanatomical changes, such as the presence of Lewy bodies and Lewy neurites appear 
first in the medulla oblongata, the pons and the olfactory bulb, then spread to the midbrain 
and lastly affect the neocortex (Braak et al., 2003). It is no surprise thus, that symptoms 
deriving from dysfunction of these brain regions may precede motor symptoms and other 
non-motor symptoms may develop in late stage disease. 
2.2.1 Olfactory dysfunction 
Olfactory dysfunction has been recognized to be an early clinical sign in patients with iPD 
and bedside testing can be easily performed by standardized odour test batteries (see part 
3.3.1). Approximately 70 - 90 % of all iPD patients present with a significant lack of odour 
discrimination and it seems to be present well before the onset of motor symptoms (Doty et 
al., 1988; Kranick and Duda, 2008), which could result in a future use of olfactory testing in 
combination with other parameters as a biomarker in putative neuroprotective therapies. A 
recent study evaluating brain glucose metabolism suggests that hyposmia is related to 
cognitive imparment due to cortical dysfunction in iPD patients and that the cognitive 
deficit in olfactory perception is at least partially responsible for diminished smell 
differentiation. Altered metabolism in the amygdala and the piriform cortex could be 
responsible for this sensory deficiency (Baba et al., 2011).  
2.2.2 Dysautonomia 
Dysautonomic features, such as seborrhoea, orthostatic hypotension, gastrointestinal or 
urinary dysfunction may occur before or after the onset of motor symptoms (Bassetti, 2010). 
Their early presence (especially urinary dysfunction, orthostatic hypotension) should 
however always challenge the diagnosis of iPD and lead to consideration of the differential 
diagnosis of atypical parkinsonian syndromes, such as multisystem atrophy (MSA) or 
progressive supranuclear palsy (PSP) (Colosimo et al., 2010).  
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Urinary dysfunction is especially debilitating for the patient and usually manifests as 
overactive bladder syndrome, which has been attributed to the degeneration of central 
serotonergic projections. It correlates with disease severity (measured by the UPDRS-III 
score) and patient age (Iacovelli et al., 2010).  
Gastrointestinal symptoms are present in more than half of iPD patients and may comprise 
constipation, dysphagia, nausea, vomiting, incomplete bowel emptying or incontinence. As 
for other dysautonomic symptoms, the prevalence in atypical parkinsonian syndromes, such 
as MSA or PSP, but also in DLB is much higher (Colosimo et al., 2010). 
Symptomatic postural hypotension is less frequent in iPD, but ~20 % of the patients show a 
drop in systolic blood pressure of more than 20 mmHg associated with postural events 
(Senard et al., 1997). If orthostatic hypotension is prominent at initial presentation, the 
diagnosis of MSA should be considered.  
While above-mentioned symptoms are likely to be verbalized by the patients, sexual 
dysfunction is not. Patients may not even be aware of the fact that erectile dysfunction and 
loss of libido are part of the non-motory symptom complex observed in iPD and these 
symptoms are therefore likely to be underreported. Nevertheless, a recent study analyzing 
the most bothersome symptoms reported by iPD patients in early stage disease (up to 6 
years disease duration) listed sexual dysfunction at place 12 of 24 and this was similar in late 
stage disease patients (Politis et al., 2010). 
2.2.3 Depression and anxiety 
Neuropsychiatric disorders, such as depression and anxiety are frequently found alongside 
with motor symptoms - approximately 40 % of all iPD patients show anxiety-related, 
depressive or combined psychopathology (Brown et al., 2011). A recently published analysis 
demonstrates a positive correlation between depression and higher UPDRS/Hoehn and 
Yahr stages. Also, other non-motor symptoms, such as anxiety, hallucinations and sleep 
disturbances were more frequently observed in depressed iPD patients (Dissanayaka et al., 
2011). Disease severity in iPD has also been shown to be positively correlated with anxiety 
and patients with young onset, gait dysfunction and postural instability were especially 
prone to develop an anxiety disorder (Dissanayaka et al., 2010) 
2.2.4 Cognitive decline and dementia 
About 40 % of all patients initially diagnosed with iPD will develop cognitive decline with 
dementia in the course of the disease (Aarsland et al., 2001). According to the current 
diagnostic criteria, the occurence of cognitive dysfunction in patients with parkinsonian 
symptoms later than 12 months after the first presentation of motor symptoms is considered 
as Parkinson’s disease dementia. When cognitive decline occurs before or within the first 
year of motor symptom onset, dementia with Lewy-bodies (DLB) has to be diagnosed rather 
then iPD (McKeith et al., 1996). Because of their histopathological similarities, it is likely that 
iPD and DLB are not separate entities, but different manifestations within the spectrum of 
disorders, which are defined by the presence of pathologic alpha-synuclein aggregates, so-
called alpha-synucleinopathies. The neuropsychological examination for Parkinson’s disease 
dementia should include specific scales which should be powered to detect cortical 
dysfunction.  For example, the Scales for Outcomes of Parkinson's disease-Cognition 
(SCOPA-COG), Parkinson's Disease-Cognitive Rating Scale (PD-CRS), and Parkinson 
Neuropsychometric Dementia Assessment (PANDA) are likely to yield a more precise 
assessment of the patient’s cognitive dysfunction than general dementia assessments 
(Kulisevsky and Pagonabarraga, 2009). 
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2.2.5 REM-sleep behaviour disorder 
REM-sleep behaviour disorder (RBD) is an especially interesting feature of iPD patients, 
because it can appear many years before the diagnosis of the disease based on classical 
motor symptoms (Claassen et al., 2010) and is observed in up to 25 % of all iPD patients 
(Gjerstad et al., 2008 JNNP). RBD is characterized by increased motor activity during REM 
sleep, which may result in vocalization and vigorous limb movements. Patients usually also 
describe a vivid and sometimes terrifying dreaming experience. Sleep disturbances as well 
as restless legs are ranked high in the list of most bothersome symptoms for early and even 
more late stage iPD patients (Politis et al., 2010). In addition, up to 50 % of iPD patients 
complain of excessive daytime sleepiness, which also can precede the manifestation of 
motor symptoms by many years (Abbott et al., 2005).  
 
Autonomic failure 
- Gastrointestinal dysfunction 
- Urinary dysfunction 
- Sexual dysfunction 
- Orthostatic hypotension 
 
Neuropsychiatric and sleep disturbances 
- Depression 
- Anxiety 
- Panic attacks 
- Impulse control disorder 
- Hallucinations 
- Psychosis 
- Dementia 
- REM sleep behavior disorder and insomnia 
- Excessive daytime sleepiness and fatigue 
 
Sensory deficits 
- Olfactory dysfunction 
- Pain 
Table 2. Non-motor features which may occur in idiopathic Parkinson’s disease. 
3. Additional exams 
Although the diagnosis of iPD can be made based purely on clinical examination, additional 
technical exams can help to differentiate other degenerative disorders, most importantly 
secondary or atypical parkinsonian syndromes.  
3.1 Imaging approaches 
3.1.1 MRI 
There are currently no MRI-criteria in clinical use for the verification of a putative iPD 
diagnosis. No single morphological marker could be identified permitting the diagnosis of 
iPD, even though several parameters exist, which help to differentiate iPD from atypical 
parkinsonian syndromes. Recent approaches combining different magnetic resonance 
parameters (such as R2* value, mean diffusivity and fractional anisotropy) have been shown 
to achieve a high accuracy for the discrimination of iPD patients and controls (Péran et al., 
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2010). It remains to be seen whether similar techniques find application in the clinical 
practice and whether they will be able to separate other entities from iPD.  
Nevertheless, conventional CT and MRI imaging has its place in the diagnostic workup for 
suspected iPD and is widely used to exclude common differential diagnoses, such as 
vascular PD, Wilson’s disease, or atypical parkinsonian syndromes (see section 4). 
3.1.2 SPECT imaging 
Imaging with radiolabeled ligands has markedly improved the functional diagnostics of 
Parkinson’s disease. PET and SPECT techniques permit to visualize the pre- and 
postsynaptic compartment of the nigrostriatal projections and thus draw a semiquantitative 
picture about functionality of these pathways. In clinical use, they are mostly used for the 
differentiation of iPD from atypical parkinsonian syndromes or from essential tremor (ET).  
The dopaminergic deficit can be quantified by a DAT-SPECT (DaTSCAN®) using [123I]-FP-CIT 
and is a measure for the presynaptic dopamine transporter in the striatal dopaminergic 
synapse (Booij et al., 1997). The DaTSCAN should be used, if the dopaminergic deficit itself is 
clinically unclear, i.e. too subtle, or if tremor is the prominent symptom, which makes the 
discrimination between iPD and ET difficult (Benamer et al., 2000). The DaTSCAN also 
correlates with the rate of dopaminergic degeneration in the course of the disease 
(Winogrodzka et al., 2001) and, similarly to the clinical presentation, the signal reduction is 
usually found with a unilateral preference. With further progression and degeneration in later 
disease stages signal reduction appears bilaterally (Fig. 1a). According to a study of 122 
patients with iPD, the DaTSCAN shows different patterns in tremor-dominant versus akinetic-
rigid iPD (Eggers et al., 2011). Unfortunately, the [123I]-FP-CIT SPECT does not reliably 
distinguish iPD from atypical parkinsonian syndromes, such as MSA, PSP, CBD and a similar 
nigrostriatal deficit is also detected in LBD (Pirker et al., 2000; Kägi et al., 2010). Other imaging 
techniques focussing on the D2-receptor expression are more useful to answer this question. 
As mentioned earlier, autonomic denervation is an early phenomenon in iPD and [123I]-MIBG 
scintigraphy is a mean to visualize the postganglionic, presynaptic sympathetic terminals. 
 
 
Fig. 1. a: DAT-SPECT; transversal section; 3 h after injection of 220 MBq [123I]-FP-CIT 
(DaTSCAN®). Left: normal dopamine transporter labeling. Right: reduced putaminal 
dopamine transporter labeling suggestive of a nigrostriatal deficit (e.g. IPD, LBD, MSA).  
b: D2-receptor-SPECT; transversal section; 1,5 h after injection of 185 MBq [123I]-IBZM. Left: 
normal D2-receptor expression with good contrast in the basal ganglia relative to cortex. 
Right: reduced D2-receptor expression with low contrast of basal ganglia relative to cortex 
(e.g.: MSA). 
Reduced tracer uptake by nerve terminals in the heart is observed in iPD already in the 
beginning of the disease and it remains fairly stable in later stages even though it does not 
seem to correlate significantly with clinical symptoms of autonomic dysfunction (Matsui et 
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al., 2006). Due to better sensitivity and the correlation to clinical progression the DaTSCAN 
currently may be more suitable in the early diagnosis of iPD than [123I]-MIBG scintigraphy.  
SPECT imaging also allows quantifying the postsynaptic dopamine receptor status, which can 
be helpful in the differentiation of iPD and atypical parkinsonian syndromes. D2 receptors can 
be imaged by application of [123I]-IBZM or [123I]-IBF and are decreased in atypical parkinsonian 
syndromes, such as MSA or PSP, but normal or even upregulated in early iPD (Kim et al., 
2002) (Fig. 1b). Imaging techniques aiming at the visualization of cerebral blood flow, such as 
[99mTc]-ECD (so-called Neurolite) or FDG, can help in the identification of corticobasal 
degeneration, where an asymmetrical reduction of perfusion in cortical areas can be revealed 
(Hossain et al., 2003) and discriminate towards PSP (Zhang et al., 2001).  
Non-dopaminergic functions are also accessible to PET and SPECT imaging, although these 
examinations are not performed routinely. For example, the 11C-WAY100635 PET can 
visualize reduced serotonin receptor expression in iPD, which has been suggested to play a 
role in iPD-associated depression, and evaluation of 11C-PK11195 binding by PET 
examination reflects microglial activation associated with iPD (Brooks, 2007). 
3.1.3 Transcranial ultrasound 
Transcranial ultrasound has meanwhile become a standard exam for the initial bedside 
diagnostics in suspected iPD. Since the first description of hyperechogenicity in the 
substantia nigra in iPD patients (Becker et al., 1995) a large number of studies confirmed 
these findings demonstrating that these alterations occur in more than two thirds of all iPD 
patients and that substantia nigra hyperechogenicity is detectable in a very early stage of 
disease (Fig. 2). Although the histopathological correlate of this alteration is still a matter of 
debate, there is evidence to suggest that increased iron deposition and/or microglial 
activation is responsible for this phenomenon. As in each ultrasound examination, the 
quantification and quality of the readout depends highly on the skill of the examiner, but as 
recent studies have shown, reproducibility in experienced sonographers is high (van de Loo 
et al., 2010). Because 10 % of healthy controls also show hyperechogenicity in the substantia 
nigra (Berg et al., 2001), the ultrasound may not serve as a screening method for a general 
population, but rather as a supporting exam in suspected iPD. 
 
 
Fig. 2. Transcranial B-Mode sonography of the midbrain (purple dotted line). Controls show 
little to no hyperechogenicity (white dotted line) in the substantia nigra (a) as compared to 
markedly increased hyperechogenicity in iPD patients (b). 
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3.2 Laboratory analysis 
Up to now, no laboratory test is available for the diagnosis of iPD and no single marker has 
been identified so far (see section 5). There is no routine workup, but assessment of serum 
copper and ceruloplasmin as well as urine copper may be indicated especially in patients 
with young onset PD, if Wilson’s disease is suspected.    
3.3 Other technical exams 
3.3.1 Olfactory testing 
Olfactory testing is an inexpensive, but useful supplementary exam and should be 
performed in each patient presenting with suspected iPD. Commercial kits are available, 
where different odorants, including trigeminal irritants and controls, are presented to the 
patient (e.g. Sniffin’ Sticks®, (Wolfensberger and Schnieper, 1999). Most patients (90 %) with 
iPD show olfactory dysfunction early in the disease course (Katzenschlager and Lees, 2004). 
There are therefore reasons to suggest olfactory testing as an early clinical biomarker for iPD 
(Morley and Duda, 2010). Olfaction can also be impaired in patients with MSA, but it seems 
to be mostly unaffected in PSP or CBD (Wenning et al., 1995; Müller et al., 2002). Therefore, 
olfactory testing can be a useful additional tool in the differentiation between iPD and 
atypical parkinsonian syndromes.  
3.3.2 Genetic testing 
If a family history of Parkinson’s disease exists or if disease manifestation occurs at a young 
age, patients may benefit from genetic counselling. Up to now, at least 6 PD susceptibility loci 
have been identified and at least 11 other genes are known to cause genetic Parkinson’s disease 
(reviewed in (Shulman et al., 2010). A recently published study identified individuals with an 
age of onset of 30 years or younger (50 years or younger in patients with Jewish or Hispanic 
ancestry) or those with a history of Parkinson’s disease in a first-degree relative as most likely 
to bear a mutation in a iPD-associated gene (Alcalay et al., 2010). These patients may undergo 
genetic testing after thorough information about possible consequences of the test results for 
family members, familial planning and prognostic considerations. 
3.3.3 Dopaminergic response test 
The histopathologically prominent nigrostriatal degeneration and the consecutive depletion 
of dopamine in the striatum can be identified as the pathoanatomical and biochemical 
correlate of the motor symptoms in iPD, most importantly of the bradykinetic symptoms. 
Thus, it is not surprising that dopamine replacement therapy initially results in transient, 
but marked amelioration of these symptoms, an effect which patients often experience as the 
“honeymoon-phase” due to the dramatic symptom reduction. Responsiveness to 
dopaminomimetic therapy is an important supportive factor for the confirmation of the 
diagnosis of idiopathic Parkinson’s disease and a lacking improvement of motor symptoms 
suggests the presence of an atypical parkinsonian syndrome, such as PSP, MSA or CBD.  
Clinical testing for dopaminergic response can be performed with levodopa (e.g. 200/50 mg 
levodopa/dopadecarboxylase inhibitor) by oral application or with apomorphine, a 
dopaminergic drug requiring subcutaneous administration. The test is usually considered 
positive, if the patient improves by at least 30 % in the UPDRS – a number which may be too 
ambitious in patients presenting only with mild symptoms (Reichmann, 2010). 
It has to be considered though, that even atypical parkinsonian syndromes may show an 
initial response to L-DOPA therapy, which usually is transient and less pronounced than in 
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iPD (Srulijes et al., 2011). Also, tremor is the symptom, which is most resistant to 
dopaminergic therapy and therefore may result only in an insufficient response.  
4. Differential diagnosis 
In the following part of this chapter, a number of clinically relevant differential diagnoses 
are discussed. The main clinical differences are presented along with the appropriate 
diagnostic tools for the discrimination against iPD. 
4.1 Progressive supranuclear palsy (PSP) 
As one of the most frequent atypical parkinsonian syndroms, PSP belongs to the group of 
so-called tauopathies, disorders which are characterized by pathological processing of the 
tau protein. Compared to iPD, PSP is still quite rare (1-6/100.000 inhabitants) (Schrag et al., 
1999; Nath et al., 2001). Clinically, at least two distinct variants can be differentiated: PSP-
parkinsonism (PSP-P) and the Richardson’s syndrome (RS). While PSP-P initially may 
present with typical iPD-features, such as tremor, bradykinesia, rigidity and even a 
temporary response to dopaminergic medication, other symptoms, such as the supranuclear 
vertical gaze palsy, postural instability and cognitive decline take center place in the later 
course of the disease (Litvan et al., 1996). In RS (the original syndrome described by 
Richardson in 1963) these additional symptoms are present in the very beginning of the 
disease (Richardson et al., 1963). The protracted appearance of these additional symptoms in 
PSP-P may complicate the diagnosis and it’s no surprise that less than 50 % of pathologically 
verified PSP-cases are not diagnosed correctly at their first visit (Osaki et al., 2004). 
 
 
Fig. 3. Characteristic MRI findings in PSP and MSA. Thinning of cerebral peduncles 
(“Mickey mouse sign”) (a) and mesencephalic atrophy (“hummingbird sign”) (b) on T2-
weighted images in PSP. Cerebellar and pontine atrophy (c), hyperintense putaminal rim (d) 
and degeneration of pontocerebellar projections (“hot cross bun sign”) (e) as observed on 
T2-weighted images in patients with MSA. 
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In clinical differentiation, the symmetrical and mostly axial presentation of bradykinesia, 
frequent falls and an initially pathological pull test for postural instability should direct 
attention towards possible PSP. A positive “applause sign” (a tendency to continue 
applauding after having been instructed to clap three times) may be useful in the differential 
diagnosis between iPD and PSP, but it has been recently recognized to be even more specific 
for CBD patients (Dubois et al., 2005; Wu et al., 2008). Pathological tracer distribution in the 
[123I]-IBZM-SPECT may also be found in PSP (see 3.1.2). On MRI examination patients with 
PSP may display a mesencephalic atrophy, which can appear as so-called “penguin sign” or 
“hummingbird sign” in the mid-sagittal section (Oba et al., 2005). On axial T2-weighted 
sections, the anteroposterior diameter of the midbrain is reduced and, together with a 
thinning of the cerebral peduncles, may result in the so-called “mickey mouse sign” (Fig. 
3a). The reduction of a-p diameter below 14 mm seems to specifically differentiate patients 
with PSP from iPD (Warmuth-Metz et al., 2001). 
4.2 Multiple system atrophy (MSA) 
As an atypical parkinsonian syndrome multiple system atrophy (MSA) has a slightly lower 
prevalence than PSP. Similar to iPD, MSA is an alpha-synucleinopathy, but here inclusions 
are found in oligodendrocytes instead of neurons (Tu et al., 1998). Because patients can 
present with a primarily parkinsonian or a primarily cerebellar phenotype a differentiation 
into MSA-P and MSA-C is clinically used. MSA-P patients can initially show typical signs of 
iPD, but additional signs, such as orthostatic hypotension, urinary incontinence and erectile 
dysfunction should be regarded as red flags for the diagnosis of MSA. Cerebellar 
dysfunction with ataxic gait and limb movements, dysarthria and sustained gaze-evoked 
nystagmus may initially lead in MSA-C patients, but may also be present or appear in the 
course of the disease in patients presenting with MSA-P. Some patients may also show 
positive corticospinal tract signs (Gilman et al., 1999). Response to dopaminergic medication 
can be initially positive, but the effects are mostly transient (Hughes et al., 1992). 
SPECT imaging using [123I]-IBZM may show decreased D2 receptor binding in MSA, but 
measurements of the striatal regional apparent diffusion coefficients (rADC) by diffusion-
weighted images on MRI scans (MRI-DWI) may be even more sensitive in differentiating 
MSA from iPD (Seppi et al., 2004). Conventional MRI in MSA-P can show a hyperintense 
putaminal rim on T2-weighted images. Cerebellar and pontine atrophy as well as a cross-
like hyperintensity on T2-weighted images (so-called “hot-cross-bun”-sign reflecting the 
degeneration of pontocerebellar projections) can also be observed in MSA-C (Fig. 3b-d)(Lee 
et al., 2004). 
4.3 Corticobasal degeneration (CBD) 
This rare tauopathy may have more common features with frontotemporal dementia (Pick’s 
disease) or PSP than with iPD, but an initial appearance with unilateral bradykinesia and 
tremor may evoke the latter differential diagnosis. Red flags for the presence of CBD are a 
slowly progressive unilateral apraxia together with dystonia and jerky movements mostly in 
the upper limb as well as a visual-tactile neglect. The so-called “alien-limb sign”, indicating 
the loss of voluntary control over one extremity, is present in about half of the patients. 
Signs of corticospinal tract degeneration, dysarthria, gait difficulties and supranuclear 
opthalmoplegia can be found in the later disease course (Rinne et al., 1994). Cognitive 
decline with development of dementia is frequent (Grimes et al., 1999). 
www.intechopen.com
 Diagnosis and Treatment of Parkinson’s Disease 
 
12 
 
Fig. 4. Characteristic MRI findings in CBD.  Asymmetric frontoparietal cortical atrophy with 
an emphasis on the central region in a conventional T1-weighted axial section (a), curved 
planar reformation or “pancake” representation of the cortex (b) or paramedian sagittal T2-
weighted image (c).  
Focal or asymmetric cortical atrophy with a frontoparietal preference may be present on 
MRI (Fig. 4) and a corresponding hypoperfusion/hypometabolism may be detected by 
SPECT/PET (see section 3.1.2). 
4.4 Essential tremor (ET) 
A positive family history, clinical responsivity to beta-blockers and small doses of alcohol 
suggests the presence of ET. Rest tremor is unusual in ET and the manifestation is mostly as 
a symmetrical, postural and kinetic tremor (Bain et al., 2000). Since tremor may be one of the 
first and sometimes solitary symptoms at initial presentation of iPD, differential diagnosis 
may be difficult.  
DaTSCAN analysis should usually be able to differentiate versus iPD by exclusion of a 
striatal dopaminergic deficit, but a clinical overlap has been suggested and it is still 
controversial whether at least a subgroup of ET patients may develop iPD and vice versa 
(Quinn et al., 2010).  
4.5 Lewy-body dementia (LBD) 
Histopathology suggests that LBD and iPD may indeed be very similar disorders and 
probably can be considered as a neuropathological spectrum of an alpha-synucleinopathy 
with Lewy bodies (Jellinger, 2009). As the name suggests, cognitive decline is the primary 
feature in LBD and – per definition – must be present before the onset of motor 
dysfunctions, which most frequently present as bradykinesia and rigidity. The clinical 
challenge is the separation from Parkinson’s disease dementia, which may occur in up to 40 
% of all iPD patients (see section 2.2.4). The term Parkinson’s disease dementia should only 
be used when dementia occurs at least 12 months after onset of motor symptoms in iPD, 
which however is an arbitrary cut-off. According to consensus criteria, LBD patients show 
also pronounced fluctuations in cognition and attention. Also, optical hallucinations can 
occur and patients can display a marked sensitivity to neuroleptic treatment (McKeith et al., 
1996; McKeith et al., 2005).  
4.6 Vascular parkinsonism 
It is now widely acknowledged that white matter changes observed in arteriosclerotic disease, 
e.g. due to long history of arterial hypertension, may be associated with the presentation of 
parkinsonian-like features. However, there are no commonly-accepted diagnostic criteria, 
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which may be due to the heterogeneity of this disorder as well as a possible coincidence of 
vascular changes and iPD. Clinically, patients may present with a slowly progressive difficulty 
of gait, while the upper extremities usually are less affected – thus the term “lower-body 
parkinsonism”. Tremor is less frequent, but patients may show a multitude of additional 
symptoms, such as corticospinal tract signs, pseudobulbar palsy, dementia or incontinence, 
depending on the distribution of the microvascular alterations (systematically reviewed in 
(Kalra et al., 2010). Rarely, symptoms occur abruptly after an ischemic incidence (Alarcón et 
al., 2004). Response to dopaminergic therapy usually is limited. 
In contrast to iPD, the native CT scan and the MRI may be helpful in the identification of 
vascular lesions and a history of arteriosclerosis, hypertension and other cardiovascular risk 
factors may be indicative.  
4.7 Normal pressure hydrocephalus (NPH) 
Because of the therapeutic consequences arising from the diagnosis of NPH and its 
relatively high prevalence, it is of high clinical relevance to differentiate this disorder from 
iPD. Recent estimates of the prevalence with ~22/100.000 inhabitants are very likely 
understated (Brean and Eide, 2008). Cognitive decline up to dementia as well as urinary 
incontinence in combination with a gait disturbance build the classical triad of symptoms 
initially described by Hakim and Adams (Hakim and Adams, 1965). Not all patients, 
however, present with all three symptoms at the initial visit, which may delay diagnosis. In 
addition, the slow, shuffling and broad-based gait shows striking similarities to the one 
observed in iPD (Bugalho and Guimarães, 2007).  
Enlarged ventricles can be observed on CT or MRI scans (Fig. 5) and the diagnostics should 
be followed by a large-volume lumbar puncture. Structured analysis of gait and cognitive 
function has to be performed before and after taking CSF. An improvement, which is most 
likely to occur in the gait analysis, favours the diagnosis of NPH and permits to identify 
patients, who will benefit of ventriculoperitoneal shunting (Bergsneider et al., 2005). 
 
 
Fig. 5. Characteristic findings in NPH.  Enlarged ventricles without pronounced global 
atrophy on CT scan (a), axial MRI T1-weighted (b) or sagittal T2-weighted images (c). 
4.8 Drug-induced Parkinsonism 
Different medications can result in a clinically apparent parkinsonism. The symptoms are 
usually symmetric and tremor is less frequent in contrast to iPD (reviewed in (Susatia and 
Fernandez, 2009). Most importantly, dopamine receptor blockers (e.g. neuroleptics or 
antiemetics) and other dopamine-depleting drugs have to be considered (Ebadi and 
Srinivasan, 1995). However, valproic acid, lithium, flunarizine as well as some SSRIs have 
also been reported to cause extrapyramidal symptoms (Susatia and Fernandez, 2009).  
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The prognosis of drug-induced Parkinsonism is rather good as most patients recover after 
discontinuation of medication. If parkinsonian symptoms are not reversible, one should 
consider the presence of iPD, which has been unmasked by the anti-dopaminergic medication.  
4.9 Other differential diagnoses 
In addition to the above-mentioned disorders, there are a number of less frequent causes for 
parkinsonian syndromes. Because basically any kind of lesion to the extrapyramidal system 
can potentially result in a parkinsonian presentation, the list of possible etiologies cannot be 
complete. Some of them have been listed as exclusion criterion in the UKPDSBB clinical 
diagnostic criteria, for example repeated head trauma, history of encephalitis, cerebral 
tumour or MPTP exposure (see Table 1). Other neurodegenerative (Huntington’s disease, 
spinocerebellar ataxia, frontotemporal dementia), neurometabolic (Wilson’s disease, Fahr’s 
disease, hypoxia) or toxin-induced (occupational manganese exposure, carbon monoxide 
intoxication) disorders can also present with signs of parkinsonism, even though usually 
other symptoms are additionally present (reviewed in (Tolosa et al., 2006)).  
5. Strategies to improve diagnostic security and early diagnosis 
The need to establish an early and reliable diagnosis resulted in a vast ongoing research 
activity to identify early biomarkers for iPD. Numerous studies focussed on serum or CSF 
samples, because these fluids can be easily collected and are readily available for large-scale 
examinations. Numerous publications document the effort to analyze levels of candidate 
proteins as putative biomarkers, i.e. alpha-synuclein, oligomeric alpha-synuclein, tau, abeta, 
DJ-1 and combinations thereof, just to name a few (Tokuda et al., 2006; Borroni et al., 2008; 
Waragai et al., 2010; Tokuda et al., 2010). A recently published large cohort study could 
show reduced alpha-synuclein levels in synucleinopathies (DLB, iPD and MSA), but was not 
able to discriminate between these different entities (Mollenhauer et al., 2011). Levels of 
dopamine metabolites (Lunardi et al., 2009), transition metals (Jiménez-Jiménez et al., 1998) 
or neurotrophic factors (Pålhagen et al., 2010) have also been quantified, but at the moment 
there is no clinically helpful single biomarker or combination of biomarkers available.  
Novel imaging techniques mainly based on MRI algorithms could move the field forward, 
but an automated analysis of several parameters appears to be mandatory and has not yet 
reached clinical practice (Jubault et al., 2009; Vaillancourt et al., 2009; Boelmans et al., 2010; 
Jubault et al., 2011).  
Next to imaging and laboratory analysis the identification of clinical markers may be even 
more important, since preclinical symptoms precede the onset of motor symptoms 
significantly. A combined strategy taking into account a cumulative score involving 
premotor symptoms, such as olfactory dysfunction, sleep disorders and neuropsychiatric 
disorders could be a promising approach and will have to be evaluated for its prognostic 
value (reviewed in (Wu et al., 2011).  
6. Summary 
The diagnosis of idiopathic Parkinson’s disease is mainly based on clinical criteria of motor 
symptoms, such as bradykinesia, tremor and rigidity.  
If these are met, other signs of atypical and secondary parkinsonian syndromes, for example 
MSA, PSP, CBD, vascular parkinsonism, NPH or LBD have to be excluded. In addition to 
clinical signs typical of these disorders, auxiliary exams, including olfactory testing, MRI 
and SPECT imaging can help to identify these entities.  
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Finally, the diagnosis of iPD is supported by prospective criteria, which have to be met 
during the course of the disease, such as levodopa response, asymmetric symptoms and 
disease progression.  
There is no single reliable biomarker for iPD available yet and a definite diagnosis currently 
can be made only by histology. 
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